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Mutations in the catalytic subunit of the mitochondrial DNA polymerase g (POLG) have been found to be an
important cause of neurological disease. Recently, we and collaborators reported a new neurodegenerative disorder
with autosomal recessive ataxia in four patients homozygous for two amino acid changes in POLG: W748S in cis
with E1143G. Here, we studied the frequency of this allele and found it to be among the most common genetic
causes of inherited ataxia in Finland. We identified 27 patients with mitochondrial recessive ataxia syndrome
(MIRAS) from 15 Finnish families, with a carrier frequency in the general population of 1:125. Since the mutation
pair W748S+E1143G has also been described in European patients, we examined the haplotypes of 13 non-Finnish,
European patients with the W748S mutation. Haplotype analysis revealed that all the chromosomes carrying these
two changes, in patients from Finland, Norway, the United Kingdom, and Belgium, originate from a common
ancient founder. In Finland and Norway, long, common, northern haplotypes, outside the core haplotype, could
be identified. Despite having identical homozygous mutations, the Finnish patients with this adult- or juvenile-onset
disease had surprisingly heterogeneous phenotypes, albeit with a characteristic set of features, including ataxia,
peripheral neuropathy, dysarthria, mild cognitive impairment, involuntary movements, psychiatric symptoms, and
epileptic seizures. The high carrier frequency in Finland, the high number of patients in Norway, and the ancient
European founder chromosome indicate that this newly identified ataxia should be considered in the first-line
differential diagnosis of progressive ataxia syndromes.
Introduction
Polymerase g (POLG) is considered to be the replicative
polymerase of mtDNA and may also participate in
mtDNA repair (Longley et al. 1998; Kaguni 2004). The
functional POLG consists of a catalytic a core and an
accessory b subunit. The catalytic subunit (POLGa) con-
tains the polymerase and exonuclease domains and an
interdomain region called “the spacer” that is suggested
to play a role in template positioning and interaction
with the b subunit (Kaguni 2004). Different mutations
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in the gene encoding the catalytic subunit, POLG1
(MIM 174763), result in a large variety of clinical phe-
notypes. Dominant and recessive mutations of POLG1
cause progressive external ophthalmoplegia (PEO [MIM
157640]) (Van Goethem et al. 2001; Lamantea et al.
2002; Luoma et al. 2004), characterized by the accu-
mulation of mtDNA deletions in muscle (Zeviani et al.
1989). Recently, POLG1 mutations, especially those af-
fecting its spacer domain, have been found to be a sig-
nificant cause of inherited neurodegenerative pheno-
types, such as sensory ataxic neuropathy, dysarthria
(Van Goethem et al. 2003a), myoclonus, seizures (Van
Goethem et al. 2003b), ataxia, and parkinsonism (Lu-
oma et al. 2004). Since neurodegeneration is often as-
sociated with aging, it is of major interest that inacti-
vation of the POLG proofreading function results in
premature aging in mice (Trifunovic et al. 2004). An-
other, recently reported clinical outcome of POLG1 mu-
tations is Alpers syndrome (Naviaux and Nguyen 2004;
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Ferrari et al. 2005), characterized by progressive neu-
rological disorder and liver failure.
We and collaborators recently reported POLG1 mu-
tations in a new neurodegenerative disorder with au-
tosomal recessive ataxia in four patients from two un-
related families (Rantama¨ki et al. 2001; Van Goethem
et al. 2004). These patients were homozygous for
two amino acid changes in POLG: W748S in cis with
E1143G. The latter is considered a polymorphism, oc-
curring in ∼3% of the North American population.
However, its functional effect in combination with the
W748S mutation is unknown. Our patients had gait
ataxia and peripheral sensory neuropathy with CNS
features, such as dysarthria, nystagmus, mild cognitive
impairment, degeneration of the central sensory path-
way, and epileptic seizures. However, typical findings of
a mitochondrial disease were lacking, since these pa-
tients had no or few abnormal fibers seen by histological
examination of muscle, and the Southern blot analysis
of their muscle DNA did not show mtDNA deletions
(Van Goethem et al. 2004). Similar findings were de-
scribed for two Norwegian patients carrying the W748S
and E1143G combination (Winterthun et al. 2005). A
closely resembling phenotype was also reported in pa-
tients homozygous for another spacer domain mutation,
A467T (Van Goethem et al. 2003b, 2004; Winterthun
et al. 2005), and in patients compound heterozygous for
the above-mentioned three mutations (Van Goethem et
al. 2004).
We studied the frequency of the W748S mutation in
Finnish patients with ataxia, as well as in the Finnish
population. We discovered that the mutation is among
the most common genetic causes of inherited ataxia in
Finland and that the carrier frequency in Finns is high.
This prompted a detailed phenotypic study of patients
with identical mutations, as well as a genealogical study
of Finnish and other European patients with the com-
bination of W748SE1143G. We present here evidence
of a pan-European ancestral mutation for this mito-
chondrial recessive ataxia syndrome (MIRAS) and sug-
gest that it is a common cause of recessive ataxia in the
European population.
Material and Methods
Subjects
This study was approved by the ethical review boards
of Turku University and Helsinki University Central
Hospital, and informed consent for sample collection
and DNA analysis was obtained from the patients. We
performed the initial mutation screening by using the
sample collection of the University of Turku, which
serves as the only diagnostic center in Finland for spi-
nocerebellar ataxia (SCA) mutations. From December
1993 to May 2004, SCA diagnostic samples from 325
patients were sent to this diagnostic center, and 306 of
these patients remained without definite SCA diagnosis
after mutation screening (for 251 samples, all of the
following mutations were screened: SCA1, 2, 3, 6, 7, 8,
10, 12, and 17; DRPLA; and FRDA [MIMs 164400,
183090, 109150, 183086, 164500, 603680, 603516,
604326, 607136, 607462, and 229300, respectively]).
Our patients consisted of these 306 undiagnosed pa-
tients with various ataxia phenotypes resembling SCAs.
Twenty-five patients with SCA8 mutations (nine of these
were dominant) were included because SCA8 repeat ex-
pansions are present in healthy controls as well, and thus
a positive finding is not enough for a definitive SCA8
diagnosis. After the initial screen, local materials from
three Finnish university hospitals were screened, and
samples from patients with conditions resembling the
previously identified patients with the POLG W748S
mutation were analyzed. We included in the present
study two previously reported Finnish families (Ranta-
ma¨ki et al. 2001; Van Goethem et al. 2004) with mem-
bers homozygous for the W748SE1143G mutations.
The British patient we included, who was compound
heterozygous for the W748SE1143G and the A467T
POLG mutations, has been described elsewhere (Van
Goethem et al. 2004). Also part of the present study
were two previously unpublished Belgian patients, who
were also compound heterozygous for the same muta-
tions. Of the 10 Norwegian patients analyzed, 2 were
described elsewhere (Winterthun et al. 2005); the others
were unpublished. Four of the Norwegian patients were
compound heterozygous for the W748SE1143G and
the A467T POLG mutations, and the remainder were
homozygous for the W748SE1143G POLG mutations.
We gathered medical and family histories of the Finn-
ish patients homozygous for the W748S mutation and
performed a genealogical study in accordance with pub-
lished criteria (Varilo 1999). We traced ancestors back
to 1850 from Finnish population registers and local
church records and marked the birthplaces of the grand-
parents on a map of Finland.
To determine the carrier frequency of the W748S mu-
tation in the Finnish population, control individuals
were screened for this mutation. Anonymous DNA sam-
ples were collected from 150 healthy Red Cross blood
donors. Of these controls, 50 were from the province of
North Karelia, 50 were from western Finland, and 50
were from the province of Ha¨me. In addition, 10 pooled
samples of genomic DNA from 10 control individuals,
collected from anonymous Red Cross blood donors,
were analyzed by solid-phase minisequencing.
To obtain the incidence of this disease in Finland, the
number of patients born in the 1950s (11 patients) was
divided by the total number of Finns born in the 1950s
(896,175 persons). The corresponding carrier frequency
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was calculated according to Hardy-Weinberg equilib-
rium, under the assumption of random mating and
nonselection.
DNA Extraction
Genomic DNA was extracted from peripheral blood
samples by routine methods. A deparaffinized histolog-
ical sample lysate was used to analyze the presence of
the mutation in one patient, as described elsewhere (Shi-
bata et al. 1988).
PCR and Solid-Phase Minisequencing Analysis
The presence of the p.W748S (c.2243GrC nucleotide
change in exon 13 of POLG1 [GenBank accession num-
ber NM_002693; sequence numbering starts from ATG])
(Van Goethem et al. 2004) and p.E1143G (c.3428ArG
in exon 21) mutations were analyzed by PCR and solid-
phase minisequencing (Syva¨nen et al. 1990). The region
of interest was first amplified by PCR with the use of
a 5′-biotinylated primer and a 3′-nonbiotinylated pri-
mer. The primer sequences for c.2243GrC were 5′-Bio-
CCATGGCAATGGACCTTA-3 ′ and 5′-GAAACAC-
CACAGGACAGGC-3′, and the primer sequences for
c.3428ArG were 5′-Bio-TTTCACCTCTGCCCAC-
CTTC-3′ and 5′-TCAAGAGGTTGGTGATCTGC-3′.
PCR was performed in 0.2 mM dNTPs; 1 mM and 0.2
mM of the nonbiotinylated and biotinylated PCR prim-
ers, respectively; and 1 U of thermostable DNA poly-
merase (AmpliTaq Gold DNA Polymerase [Applied Bio-
systems]), in 50 ml of buffer. The PCR program for
c.2243GrC included an initial cycle at 94C for 10
min, followed by 35 cycles at 94C for 30 s, 57C for
30 s, and 72C for 30 s, and a final elongation at 72C
for 10 min. The amplification protocol for c.3428ArG
was similar, except for an annealing temperature of
60C. Detection of the c.2243GrC mutation and the
c.3428ArG polymorphism was performed by solid-
phase minisequencing as described elsewhere (Suoma-
lainen and Syva¨nen 2000), except that we used 0.1 mCi
of the [3H]dNTPs (Amersham Biosciences). In brief, the
biotinylated PCR product was bound to streptavidin-
coated microtiter wells (Thermo Electron) and was de-
natured. A detection step primer was hybridized so that
its 3′ end annealed just adjacent to the mutation site. A
primer-extension reaction, with the use of one [3H]-
labeled dNTP and thermostable DNA polymerase (Dy-
nazyme [Finnzymes]), was performed to identify the
nucleotide at the mutation site. The detection primer
was denatured, and the incorporated radioactivity was
then measured in a liquid scintillation counter. The
counts-per-minute values reflected the amount of the
nucleotide present in the PCR product. The detection
primer for c.2243GrC was 5′-TGTGAGGCAGCT-
TGAAAAAC-3′, and the radioactive nucleotides used
to detect the mutation were [3H]dCTP (wild type) and
[3H]dGTP (mutation). For c.3428ArG, we used de-
tection primer 5′-CAGCGCGGTAGCGGTCCTCC-3′
and nucleotides [3H]dTTP (wild type) and [3H]dCTP
(mutation).
The initial screening of the 306 ataxia samples for
p.A467T (c.1399GrA in exon 7) was performed by a
TaqMan 5′ nuclease assay by use of the forward and
reverse primers 5′-CGGGAGATGAAGAAGTCGTTG-
ATG-3′ and 5′-AAGGCCTGGCTACCTCTCT-3′, re-
spectively; the normal and mutation-specific TaqMan
MGB probes 5′-VIC-TCTGGCCAATGATG-3′ and 5′-
FAM-ATCTGACCAATGATG-3′, respectively; and a
nonfluorescent quencher at the 3′ end of each probe. The
amplification and allelic discrimination were performed
in an Mx3000P Real-Time PCR System (Stratagene). By
use of TaqMan Universal PCR Mix (Applied Biosys-
tems), 50 ng of DNA was amplified in 25 ml of buffer,
and the PCR program included an initial cycle at 95C
for 10 min, followed by 42 cycles at 92C for 15 s and
60C for 1 min.
The remainder of the samples was screened for p.A467T
by PCR and solid-phase minisequencing with methods
similar to those for p.W748S and p.E1143G. The PCR
primers used were 5′-Bio-ACCAGAACTGGGAGCGT-
TAC-3′ and 5′-CTACCTCTCTCCTGAGAGCA-3′, and
the annealing temperature for PCR was 52C. The de-
tection primer was 5′-CAGCTGGCAGGCATCATTGG-
3′, and the radioactive nucleotides were [3H]dCTP (wild
type) and [3H]dTTP (mutation).
DNA Sequence Analysis
The exons of POLG1 were sequenced using intronic
primers reported elsewhere (Van Goethem et al. 2001),
by automated nucleotide sequencing with the BigDye
terminator Ready Reaction Kit v.3.1 on the Applied Bio-
systems 3730 DNA Analyzer, as described by Luoma et
al. (2004).
Haplotype Analyses
To determine the haplotypes of our patients with
the W748S mutation, we analyzed 14 polymorphic
dinucleotide markers flanking the POLG1 gene. The
markers used were D15S154, D15S999, D15S655,
D15S979, D15S1045, D15S276, D15S299, D15S510,
D15S542, D15S560, D15S202, D15S116, D15S532,
and D15S127. Figure 1 shows their distances from
POLG1. PCR was performed in 0.2 mM of dNTPs,
0.33 mM of PCR primers, 0.8 mCi of [33P]dATP, and 1
U of thermostable DNA polymerase (Dynazyme [Finn-
zymes]), in 30 ml of buffer. The PCR program included
an initial cycle at 94C for 3 min, followed by 30–33
cycles at 94C for 30 s, 48C–62C (optimized for each
primer pair separately) for 30 s, and 72C for 30 s, and
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a final elongation at 72C for 10 min. The radioactive
PCR products were electrophoresed through denaturing
6% polyacrylamide gels, and the film (Biomax MR
films [Kodak]) was exposed by autoradiography for 1–
2 d. In addition, intragenic SNPs were analyzed from
the original sequencing data of the patient samples with
the W748S mutation.
Bacterial Cloning of POLG1 Alleles
By bacterial cloning and sequence analysis of the re-
sulting clones, we determined which SNPs were lo-
cated in the same allele as W748S or E1143G. A PCR
product containing exons 11–13 (with W748S and SNPs
rs2072266 and rs2072267 [SNP numbers are from
NCBI dbSNP]) was obtained using primers 5′-GAG-
TGGGCATCTGGTAATCA-3′ and 5′-TGTGGGCC-
TTGAGCAGAAT-3′, and a PCR product containing
exons 19–21 (with E1143G and SNPs rs2246900 and
rs2302084) was obtained using primers 5′-AGCCG-
TTTCTTCCTCTGA-3′ and 5′-CCAAAGCCCCACA-
TAGGAGCACA-3′. PCR was performed in 0.2 mM
dNTPs, 1.7 mM of PCR primers, and 0.5 U of DNA
polymerase (Dynazyme EXT [Finnzymes]), in 30 ml of
buffer. Standard cycling conditions were used, with an
annealing temperature of 58C. The PCR products were
then cloned separately into pCR 2.1-TOPO vectors (In-
vitrogen), and the plasmid DNA was extracted from the
clones with QIAprep Spin Miniprep Kit (Qiagen) and
was subjected to sequence analysis as described above.
Results
DNA Analyses of Finnish Samples
We identified 27 Finnish patients with MIRAS, from
15 different families, on the basis of DNA analysis and
the medical histories of the patients’ close relatives. In
all these families, the patients were homozygous for the
W748S and E1143G combination. One of the patients
with MIRAS had been previously identified as a carrier
of an SCA8 expansion, with no family history of SCA8.
Eleven of the patients were born in the 1950s, for a
birth incidence of 1:81,500. On the basis of this inci-
dence, the corresponding carrier frequency was calcu-
lated to be 1:140. Of the 500 control chromosomes
analyzed, 2 chromosomes carried the W748S POLG mu-
tation. Therefore, the carrier frequency of W748S was
estimated to be 1:125. Of the 300 control chromosomes
screened, 8 were carriers of the E1143G amino acid
change, which gives an allele frequency of 2.7% and
shows that E1143G is a frequent polymorphism, not
always accompanied by W748S.
From the screened patient material, we also identified
three patients heterozygous for W748S. Samples from
these patients were forwarded for sequence analysis of
the entire POLG1. However, no further mutations were
identified. In addition, one patient was identified as het-
erozygous for the A467T mutation.
Clinical Manifestations
Because of the high number of patients identified as
homozygous for W748SE1143G, we studied the man-
ifestations of the disease from medical records. Four typ-
ical patient histories have been reported elsewhere (Ran-
tama¨ki et al. 2001; Van Goethem et al. 2004). The two
patient case reports that follow, being two extremes of
the disease manifestation, demonstrate the clinical het-
erogeneity of MIRAS.
Patient V.—This patient was the fifth of five children
of healthy, nonconsanguineous parents. Birth and early
milestones were normal. At age 16 years, she had an eye
infection and a slight head injury within a 1-wk interval.
One week after the injury, she suddenly developed re-
current tonic-clonic seizures. At medical examination,
she had a slight fever, she was mildly confused, her abil-
ity to maintain attention was reduced, and her relatives
reported a change in personality. She also had symp-
toms suggesting a lesion of the left hemisphere: weakness
of the right limbs and homonymous hemianopia. CT
findings were normal. An electroencephalogram (EEG)
showed slow wave activity with spikes bilaterally in the
occipital region, with spreading to the left hemisphere.
She was thought to have herpes encephalitis, even
though she lacked herpes antibodies and EEG findings
typical for that condition. EEG background abnormal-
ities and some neuropsychological changes persisted
thereafter, but the symptoms indicating a hemispheric
lesion resolved. Despite anticonvulsive medication, she
continued to have epileptic seizures. She also had de-
creased deep-tendon reflexes in the lower extremities but
only mild defects of coordination. Magnetic resonance
imaging (MRI) at age 23 years showed symmetric, bi-
lateral high-signal-intensity lesions in the cerebellum and
thalamus. She developed gait and limb ataxia and dys-
arthria, which were prominent at age 31 years. In ad-
dition, she had some choreoathetoid movements, and
her cognitive impairment had progressed: she had child-
like conversational skills, and neuropsychological tests
showed impairments of memory and visual reasoning.
Muscle strength, vibration sense, and touch sensation
were all normal. At age 34 years, she was using a wheel-
chair and walked short distances with a walker. Her
involuntary movements had aggravated. Epileptic sei-
zures gradually became frequent, and, at age 37 years,
she was hospitalized permanently. In the hospital, she
had dysphagia and was paranoid, and her cooperation
and general condition gradually worsened. The patient’s
sister also suffered from seizures and cognitive decline,
with a similar onset of symptoms, and she died at age
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Figure 1 Haplotypes of the Finnish, Norwegian, British, and Belgian patients. Haplotype A and the core haplotype are shown in pink.
Haplotypes B and C are shown in blue and yellow, respectively. a, The DNA marker names are written without “D15S.” Proper names can
be obtained by placing “D15S” in front of each number shown. b, Four Finnish patients with haplotypes very similar to that of patient D9
are not shown. c, One Norwegian patient with a haplotype very similar to that of patient P3 is not shown.
31 years. At the time, the sister’s symptoms were as-
sumed to be a result of encephalitis in a postencephalitic
state. The three other sisters were unaffected at 39, 38,
and 35 years of age. The patient’s cousin had died at
age 45 years and was diagnosed with possible Leigh
disease on the basis of neuropathological findings.
Patient D10.—At age 45 years, this previously healthy
man sought medical advice because of a feeling of numb-
ness and weakness in the lower extremities when walk-
ing. The symptoms had gradually worsened during 3–
4 years. He also complained of memory loss during the
previous year. At examination, muscle strength was nor-
mal, vibration sense was slightly impaired in the lower
extremities, and deep-tendon reflexes were absent in the
lower extremities but normal in the upper limbs. Rom-
berg test was negative, and heel-to-shin coordination
test was normal, but the patient had some problems
with balance when standing on one leg. A moderate sen-
sory-motor polyneuropathy was diagnosed by electro-
neuromyography (ENMG). CT showed mild cerebellar
atrophy and hypodense changes in both cerebellar hemi-
spheres. At age 54 years, his balance problems had grad-
ually aggravated, he was suffering from frequent falls,
and he had dysarthria. Mild atrophy of the cerebellum
was seen on brain CT. He was then diagnosed with cer-
ebellar ataxia and cognitive impairment, in addition to
the previously diagnosed polyneuropathy. He was also
obese and had hyperlipidemia. Psychiatric symptoms,
hallucinations, and paranoia were later manifestations
of the disease after age 57 years.
Patients overall.—Table 1 summarizes the clinical fea-
tures of 19 patients from 14 different families. Four of
the patients (F2, III-7, III-5, and III-4) have been reported
elsewhere (Rantama¨ki et al. 2001; Van Goethem et al.
2004). The median age at onset of MIRAS was 28 years;
the range was 5–41 years. Progressive gait unsteadiness
was the most common first symptom of the disease.
These patients had been experiencing balance problems
for several years before the first medical examination.
They usually presented with sensory ataxia and either
decreased or absent deep-tendon reflexes in the lower
extremities. Besides gait unsteadiness, epilepsy and neu-
ropathy (i.e., neuropathic sensations) were other com-
mon initial features of MIRAS, and these sometimes oc-
curred before the onset of gait unsteadiness. In a few
cases, epilepsy preceded other prominent symptoms by
110 years.
Symptoms suggesting cerebellar dysfunction, such as
ataxia, dysarthria, nystagmus, or other eye-movement
abnormalities, were sometimes noticeable at the first ex-
amination, whereas, in other cases, they developed later.
Eye-movement abnormalities were typically mild but in-
cluded ataxic, saccadic, or nystagmoid eye movements;
supranuclear eye-movement abnormality; and restricted
eye movements suggestive of central origin. All patients
developed ataxia and features of cerebellar speech (dys-
arthria in all patients and impaired speech volume con-
trol in four patients). Muscle strength was typically good
until the late stages of the disease.
The cognitive impairment observed in these patients
was mild to moderate. The psychiatric symptoms ranged
from denial of symptoms to severe depression, anxiety
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Figure 2 Birthplaces of the grandparents of the Finnish patients
homozygous for the W748S POLG mutation, on a map of Finland.
Haplotype A is concentrated in the late-settlement area, whereas hap-
lotypes B and C cluster solely on the western and southern coastlines.
The southeastern Karelia belongs presently to Russia and is therefore
indicated as separate on the map.
disorder, aggressivity, hallucinations, and paranoia. In-
voluntary movements were described as choreoathe-
toid movements of the limbs, myoclonus, head tremor,
tremor of the limbs (also at rest), and involuntary facial
movements.
Neuropathic pain was experienced by some of the
patients. ENMG was performed for 15 patients, and
they all had moderate to severe sensory neuropathy in
the lower extremities. In addition, the sensory nerves of
the upper limbs and the motor nerves of the lower ex-
tremities were also slightly affected in most cases. The
neuropathy was mostly of the axonal type. All four pa-
tients who did not undergo ENMG had decreased or
absent deep-tendon reflexes in the lower extremities.
Of the 19 patients, 18 underwent at least one brain
MRI or CT. Twelve patients had bilateral white-matter
changes in the cerebellar hemispheres at age 23–49
years: high-signal-intensity lesions on MRI or hypodense
lesions on CT. Five patients without these lesions had
at least minor infratentorial, cerebellar, or vermis atro-
phy. Altogether, atrophy was suspected in 16 patients.
Thalamic lesions were seen on the MRI of seven patients.
Few patients had cortical atrophy or enlarged lateral
ventricles.
Muscle was biopsied from eight patients, and features
typical of denervation were present in some of the pa-
tients. Most often, muscle biopsy and its histological
analyses or lactate measurements were not done, since
the disease resembled SCAs, not mitochondrial diseases.
None of the analyzed samples showed morphological
changes clearly suggestive of a mitochondrial disease.
Results from histochemical activities of cytochrome oxi-
dase, succinate dehydrogenase, and nicotinamide ade-
nine dinucleotide–tetrazolium reductase were available
for three, two, and one patients, respectively. The find-
ings did not support the diagnosis of a mitochondrial
disease, except in one patient, who had few fibers of
ragged-red type. Results of long-range PCR have been
reported and discussed elsewhere (Van Goethem et al.
2004); low amounts of mtDNA deletions were seen in
the muscle of two patients. The lactate levels in the cer-
ebrospinal fluid or blood were occasionally marginally
elevated but were not measured in most patients. The
EEG findings were abnormal for 11 patients, who all
had background EEG abnormalities, and were normal
for 1 patient.
Haplotype Analysis
Figure 1 shows the results of the haplotype analysis.
All the Finnish patients shared a short, common core
haplotype of four polymorphic dinucleotide markers, ex-
tending over a chromosomal region of ∼280 kb. How-
ever, the shared homozygous haplotype extended 17.6
Mb in some patients. Outside the common core region,
three different distal haplotypes with DNA marker al-
leles in linkage disequilibrium (LD) could be identified
in the Finnish patients for markers D15S560–D15S532:
haplotype A with 3-2-2-2/1, haplotype B with 1-3-3-2,
and haplotype C with 1-4-3-1. Haplotype A was found
in the majority of chromosomes: altogether, in 24 of the
31 chromosomes analyzed. Haplotypes B and C were
seen in three and four chromosomes, respectively.
Figure 2 shows the birthplaces of the grandparents of
the Finnish patients (data available for 41 grandparents).
Grandparents of patients with haplotype A have birth-
places concentrated in the late-settlement area, the part
of Finland that became permanently inhabited only in
the 16th century. Grandparents of patients with hap-
lotypes B and C have birthplaces solely on the western
and southern coastlines, respectively. The genealogical
study reaching back to 1850 revealed no recent common
ancestors between the patients.
In addition to the Finnish homozygotes for W748S
from 14 different families and the three Finnish hetero-
zygotes for W748S, we analyzed the haplotypes of 10
Norwegian patients, two Belgian patients (patients 32
and 36), one British patient (patient 26), all carrying at
Hakonen et al.: Common European Mitochondrial SCA 437
Table 2
SNP Haplotypes of Finnish, British, and Belgian Patients
SNP Intron Frequencya Finnish Britishb Belgianc
rs2307438 21 .463 G/G T/G G/G
E1143G … .026 G/G G/A G/A
rs2302084 19 .336 C/C C/T C/T
rs2246900 19 .305 G/G G/A G/A
rs2307449 18 .463 C/C C/A C/A
rs2307433 17 .548 Ins/Ins Ins/Del Ins/Del
W748S … … C/C C/G C/G
rs2072266 12 .361 C/C C/T C/Td
rs2072267 11 .54 C/C C/T C/T
rs3176183 9 .323 Ins/Ins Ins/Del Ins/Del
NOTE.—Bold typeface emphasizes the similarity between patients.
Del p deletion; Ins p insertion.
a Allele frequencies according to the SNPs of the Finnish patient.
b Patient 26.
c Patients 32 and 36.
d Data available only for patient 32.
least one allele of W748SE1143G. All the Norwegian
patients shared the core haplotype with the Finns, over
a region of 1200 kb (fig. 1). Haplotype B, also found in
the Swedish-speaking population of the Finnish west-
coast, was the major haplotype in Norwegian patients,
with seven identified chromosomes. Some remnants of
haplotype B were seen in three chromosomes, and hap-
lotype C was seen in three chromosomes. An additional
amino acid variant in POLG, Q497H, cosegregated with
haplotype B in both the Norwegian and the Finnish pa-
tients. Since remnants of the Finnish haplotypes were
also seen in the dinucleotide marker analysis of the Bel-
gian and British patients, we completed the data with
intragenic SNPs. Figure 1 and table 2 show the dinu-
cleotide and SNP haplotypes of the European patients,
respectively. One allele of the British and Belgian pa-
tients shared the intragenic SNP haplotype and the
immediate gene vicinity with the Finns and the Nor-
wegians. In the second allele, the Belgian and British
patients shared a common haplotype of ∼2 Mb, which
was different from that of the Finns. By allele-spe-
cific cloning and sequencing, we showed that the G
(rs2246900) and C (rs2302084) actually resided in the
same allele with E1143G, and that C (rs2072266) and
C (rs2072267) were found in the same allele with
W748S in the British patient. These data strongly in-
dicate that the short core SNP haplotype is associated
with the W748SE1143G allele, whereas the 2-Mb
common allele is associated with the A467T muta-
tion, providing evidence that the British and Belgian dis-
ease chromosomes originate from the same common
founder as the disease chromosomes of the Finns and
Norwegians.
Discussion
We demonstrate here that defective mtDNA polymerase
is a frequent cause of recessive ataxia, with a carrier
frequency of 1:125 in Finland. We detected a clear foun-
der effect with the W748S mutation allele in Finland,
but the Finnish core haplotype was also shared by pa-
tients from Norway, the United Kingdom, and Belgium.
The common ancient European origin of the disease
chromosome suggests that this is a frequent cause of
recessive ataxia in Europe and not solely restricted to
and enriched in Finland. We have named the POLG1-
associated ataxia syndromes “MIRAS” (which denotes
“mitochondrial recessive ataxia syndrome”).
Our initial findings of a few patients who have ataxia
with the W748S mutation (Van Goethem et al. 2004)
prompted us to analyze all those samples that had been
sent for SCA DNA diagnostic testing during the years
1993–2004. These samples represented all of Finland,
with a population of 5.2 million, since the SCA analyses
were concentrated at a single diagnostic center in the
country. We identified altogether 15 families, with 27
patients, and determined the carrier frequency to be
1:125. This correlated well with the calculated birth
incidence, 1:81,500. To date, SCA8 and SCA7 have
been the most prevalent SCAs in Finland, with nine and
six autosomal dominant families described, respectively
(Juvonen et al. 2002, 2005), and infantile-onset spi-
nocerebellar ataxia (IOSCA) has been the most common
pediatric form, with 22 patients described (Koskinen et
al. 1994; T. Lo¨nnqvist, personal communication). The
most common hereditary ataxia worldwide, Friedreich
ataxia (Harding 1981; Durr et al. 1996), is rare in Fin-
land, with seven identified patients. Our results establish
MIRAS as the most prevalent juvenile- or adult-onset
ataxia type in Finland.
To study the population history of the newly iden-
tified disease, we determined the haplotypes of the Finn-
ish patients with MIRAS. The mutation was invariably
associated with the E1143G variant—a frequent poly-
morphism with an allele frequency of 3% in Finns. The
question of whether E1143G has a functional effect,
synergistic with or antagonistic to W748S, awaits func-
tional studies. All the Finnish patients homozygous for
W748SE1143G allele shared a short core haplotype
of ∼280 kb, which suggests an ancient common founder
for the mutation. Those diseases belonging to the Finn-
ish disease heritage (Norio et al. 1973; Norio 2003)
that share a haplotype of 2–3 Mb date back to the first
bottleneck of the Finnish population in the first millen-
nium (Varilo 1999). This suggests that the common an-
cestor with MIRAS for Finnish haplotypes most likely
lived 12,000 years ago. Furthermore, outside the com-
mon chromosomal core region, three major haplotypes
with different alleles in LD with the core region extend
to cover a region of ∼10 cM. This is exceptional for a
Finnish disease, in which usually one major disease hap-
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lotype has spread within Finland from a single founder.
The three long areas of LD suggest that the MIRAS
disease chromosomes may have been introduced to the
Finnish population on three independent occasions,
each occurring rather recently, ∼10–30 generations ago
(Varilo 1999), with subsequent enrichment of separate
disease alleles within the country. This is supported by
the localization of the birthplaces of the patients’ grand-
parents to different sites of the country. In brief, the
introduction of the disease chromosomes to the Finnish
population on three different occasions is supported by:
(1) LD extending over a similar chromosomal distance
in all three Finnish haplotypes, suggesting a similar age
for all the haplotypes, (2) the relatively small amount
of haplotypes B and C, indicating that neither of these
haplotypes gave rise to the other haplotypes, and (3)
the absence of any intermediate haplotypes (with only
a telomeric or centromeric recombination) that would
support the evolution of one haplotype to another
within Finnish borders.
The distant ancestors of the Finnish patients prompted
us to look at non-Finnish patients. The POLG W748S
mutation has been recently described in Italian patients
with Alpers syndrome, as well as in British and Nor-
wegian families with ataxia phenotypes (Van Goethem
et al. 2004; Ferrari et al. 2005; Winterthun et al. 2005),
usually occurring as a compound heterozygous reces-
sive mutation. All these chromosomes also carried the
E1143G mutation. We studied the associated haplo-
types of Finnish, British, Belgian, and Norwegian pa-
tients and identified a short, common intragenic SNP
haplotype in all these samples, which suggestively
continued to the immediately adjacent chromosomal re-
gion. These results strongly suggest that all our Euro-
pean cases have a common ancient founder. Interest-
ingly, the Finnish west-coast haplotype, encountered in
the Swedish-speaking Finnish population, had at least
a 1.2-Mb region of identity with the major haplotype
in Norway, which suggests a relatively recent relocation
of a Norwegian or other Scandinavian ancestor to Fin-
land. These chromosomes also carried a third POLG
amino acid variant, Q497H, which was absent in the
other haplotypes. These data suggest migration of the
founder population within Scandinavia. Furthermore,
the common core haplotype of the Finns and Norwe-
gians was considerably longer than the shared haplotype
of the western European samples, indicating a later
branching of the northern haplotypes from the ancient
European ancestor. The common founder in western
and northern Europe and the high number of Norwe-
gian patients suggest that W748SE1143G is a com-
mon cause of ataxia in Europe.
In our non-Finnish patients, the W748S allele was
often compound heterozygous with another POLG
spacer-domain mutation, A467T. This amino acid var-
iant occurred with an allele frequency of 0.6% in the
Belgian population (Van Goethem et al. 2003a) and
!0.2% in the Finnish population (Luoma et al. 2005).
Interestingly, we saw a common A467T haplotype of
∼2 Mb in the British and Belgian patients, who were
not known to be related. Remnants of this haplotype
were also seen in two Norwegian patients but not in
the other two Norwegians with the same mutation. Our
limited material did not allow us to conclude whether
the A467T allele would have spread from an ancient
founder over Europe. Further studies on larger groups
of patient are warranted.
Mitochondrial diseases are known for their clinical
heterogeneity. However, this is most often related to
mtDNA mutations and is explained by variable loads
of mutant mtDNA in different tissues and patients.
In the case of MIRAS, all our patients were homozy-
gous for the same recessive mutation in the nuclear
POLG1 gene, but the phenotype was still surprisingly
variant, resembling the variance in diseases caused by
an mtDNA mutation. The onset of the disease was most
often at ∼30 years of age, with sensory axonal poly-
neuropathy or balance disturbances, followed by pro-
gressive cerebellar ataxia. Epilepsy and cognitive de-
fects, sometimes accompanied by psychiatric symptoms,
were often but not always present. The progression of
the disease varied, but occasionally it was quite ra-
pid, necessitating permanent hospitalization before age
50 years. Sometimes, the symptoms started already in
childhood or adolescence and manifested with an acute
incident of epilepsy. Epilepsy could be the only symptom
in a patient for years, sometimes developing to treat-
ment-resistant grand mal seizures, recurrent status epi-
lepticus, and death. Also in such cases, ataxia mani-
fested during the late 3rd decade of life. The mildest
manifestation of the same homozygous W748S allele
was sensory polyneuropathy, developing during the 5th
decade of life. In the later course of the disease, the
clinical symptoms and signs of different patients were
alike, with the exception of epilepsy, which was seen in
50% of cases. The abnormal eye movements were not
typical for external ophthalmoplegia but were mainly
coordination problems of central origin. The MRI find-
ings, initially described in our previous reports of the
index patients (Rantama¨ki et al. 2001; Van Goethem et
al. 2004), were established here as typical for the dis-
ease. Most cases showed symmetrical lesions of high
signal intensity in the white matter of the cerebellum
and minor atrophy of the cerebellum or the vermis,
sometimes combined with symmetrical high-signal le-
sions of the thalami. Mitochondrial disease was some-
times suspected on the basis of clinical findings, but
characteristic histological and biochemical findings were
lacking. In one patient, coexistence of an SCA8 repeat
expansion and homozygosity for the W748S mutation
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Table 3
Clinical Features of Three Autosomal Recessive Ataxias:
MIRAS, Friedreich Ataxia, and IOSCA
Clinical Feature MIRAS
Friedreich
Ataxia IOSCA
Age at onset (years) 5–50 !25a 2–3
Ataxia   
Cerebellar dysarthria   
Lower-limb areflexia   
Sensory axonal neuropathy   
Cognitive impairment  () 
Pes cavus ()  
Involuntary movements:
Athetosis ()  
Myoclonus  () 
Extensor plantar response ()  
Muscle weakness ()  
Epilepsy   
Cardiomyopathy, scoliosis, diabetes   
Ophthalmoplegia ()  
Sensorineural hearing loss () () 
Optic atrophy  () 
NOTE.—  p present; () p present in only a few patients; p
not present.
a Age at onset for atypical cases is 25–51 years.
did not act synergistically; the patient’s disease was typ-
ical for MIRAS. Overall, MIRAS with the homozygous
W748SE1143G mutation has typical clinical features
but shows significant variability uncommon for an au-
tosomal recessive disorder, leading to misdiagnoses of,
for example, Huntington chorea, Leigh disease, hered-
itary neuropathy, or herpes encephalitis.
The clinical features of MIRAS are indistinguishable
from the disease group of autosomal dominant cere-
bellar ataxias (ADCAs), known as “SCAs” in genetic
nomenclature. Gait and limb ataxia, dysarthria, poly-
neuropathy, hyporeflexia, nystagmus, cognitive impair-
ment, and epilepsy are all clinical features of ADCAs
(Harding 1983; Scho¨ls et al. 2004). Clinical symptoms
of MIRAS most closely resemble two other recessively
inherited SCAs, Friedreich ataxia and IOSCA, although
MIRAS has a later onset. Table 3 summarizes the clin-
ical features of these three ataxias (Harding 1981; Kos-
kinen et al. 1994; Durr et al. 1996). Friedreich ataxia
is caused by a defect in frataxin, a mitochondrial pro-
tein involved in iron homeostasis (Campuzano et al.
1996; Foury and Cazzalini 1997). IOSCA is a severe
infantile hereditary ataxia, which has been recently as-
sociated with a mutation in the mitochondrial replica-
tive helicase Twinkle (K. Nikali, A. Suomalainen, J.
Saharinen, M. Kuokkanen, J. N. Spelbrink, T. Lo¨nn-
qvist, and L. Peltonen, unpublished data). This finding
links IOSCA closely to the same pathogenetic mech-
anism as MIRAS—that is, mtDNA maintenance. In
IOSCA and MIRAS, histological abnormalities sugges-
tive of mitochondrial dysfunction were not seen in the
patients’ muscle samples, and no mtDNA deletions were
detected by Southern blot analysis. So far, no data about
mtDNA mutations in the brain have been available for
these syndromes. The two proteins of mtDNA main-
tenance, POLG and Twinkle, seem to have a crucial role
in the survival of cerebellar neurons, and defects of these
proteins are common causes of hereditary ataxia. Fur-
thermore, the similarity between the three mitochon-
drial recessive ataxia types—Friedreich ataxia, IOSCA,
and MIRAS—suggests that they form a new impor-
tant group of hereditary ataxias.
In conclusion, we have provided here comprehensive
genealogical and clinical details for a newly identified
hereditary ataxia. The Finnish MIRAS phenotype was
surprisingly variant, ranging from late-onset polyneu-
ropathy to acute encephalopathy of adolescence. This
could be the result of individual differences in defence
mechanisms against cellular stresses, mtDNA haplo-
types, or variants in the POLG-associated proteins, and
it remains to be studied in detail. The high carrier fre-
quency of the disease in Finland, the high number of
patients in Norway, and the ancient European founder
chromosome indicate that MIRAS should be considered
for first-line genetic testing of patients who have ataxia
with a suspected recessive disease. Furthermore, our
data strongly suggest that mutations in POLG1 are
emerging as an important general cause of recessively
inherited ataxias of the spinocerebellar type.
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